Rheumatoid arthritis (RA) is associated with a higher rate of heart failure subtypes, according to a study published online ...
Rheumatoid arthritis (RA) is associated with a higher rate of heart failure subtypes, according to a study published o ...
The following is a summary of “Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity,” published in the ...
For patients with heart failure with preserved ejection fraction, tirzepatide yields a reduced risk for a composite of death from cardiovascular causes or worsening heart failure.
Understanding how patients with heart failure with preserved ejection fraction (HFPEF ... Key mortality risk factors, including age, gender, body mass index, burden of co-morbidities, and coronary ...
[18] All of these factors ... and ejection fraction ≥45% who were hospitalized for heart failure during the last 6 months or had persistent class III or IV symptoms. As with the CHARM-Preserved ...
SGLT2 inhibitors plus finerenone may have a protective effect against cardiovascular events in patients with HFpEF or HFmrEF.
Our top content from the 100th annual American Heart Association (AHA) Scientific Sessions included exclusive expert insights ...
Industry-First Capabilities Combined: Medera’s Novoheart has a unique human-based mini-Heart technology platform for disease modelling and drug screening with a track record of supporting FDA IND and ...
A recent case published in the journal ACG CASE REPORTS JOURNAL found a possible risk of colonic ischemia caused by the usage ...
Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown to reduce the risk of worsening ... obese patients with heart failure with preserved ejection fraction (HFpEF) – a particularly ...
In this interview, Yehuda Handelsman, MD, highlights key updates to the Diabetes, Cardiorenal, and Metabolic (DCRM) guidelines in DCRM 2.0, shaped by global collaboration and recent clinical insights.